ApaTech has 'Best Management Team' says FastTrack
20 November 2009
ApaTech, the rapidly growing orthobiologics company, was awarded ‘Best Management Team’ prize by the judges at the FastTrack 100 Awards Dinner in London last night.
In October 2009 the Company was recognized as Britain’s fastest growing medical technology company for the third year running in the Sunday Times Fast Track 100 fastest growing private technology companies review, and last night’s award is an additional accolade for ApaTech.
Simon Cartmell, ApaTech CEO commented: “I think this is a great tribute to all the managers in the Company, that they have been recognized in such an obvious way. This award speaks to the strength of our culture and the passion we all share for this business.”
ApaTech is the developer and manufacturer of Actifuse®, a unique fully synthetic silicate substituted calcium phosphate bone graft material for orthopaedic, spinal, dental and craniomaxillofacial applications. The Actifuse scaffold mimics the body’s natural bony structure and accelerates the growth of high quality bone. Actifuse is being used by surgeons in more than 30 countries around the world.
Ends
Further Information:
ApaTech +44 20 8731 4640
Simon Cartmell, CEO
simon.cartmell@apatech.com
www.apatech.com
Waughton +44 20 7796 9999
Robin Hepburn
rhepburn@waughton.com
www.waughton.com
Notes to Editors:
About ApaTech®
ApaTech is a company specializing in synthetic bone repair materials for orthopedic and dental applications. With operations in London, England, Foxborough, Massachusetts, USA, and Berlin, Germany, ApaTech is a world leader in research and development of bone graft technologies. The company has enjoyed strong commercial success globally with products sold in 33 countries.
ApaTech has developed and commercialized a novel silicate substituted calcium phosphate bone graft material, Actifuse®. Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive, osteostimulatory and bioactive qualities resulting in accelerated bone growth. The Actifuse technology platform exemplifies the Company’s leadership in applying the science of silicon to bone graft technologies. ApaTech is backed by international investors Encore Ventures and Healthcor and following its formation in 2001, the Company has raised more than $60m from investors.
ApaTech is committed to delivering shareholder value by using its scientific leadership to deliver targeted solutions to physicians, allowing them to significantly improve patient outcomes.
ApaTech has received several corporate business and research awards, including the Frost & Sullivan ‘2009 North American Device Biologics Company of the Year’ as a result of its success in the US orthobiologics market. More recently, ApaTech was awarded 3rd place in the UK Deloitte Technology Fast 50 (2009), in addition to being recognized as Britain’s fastest growing medical technology company 3 years running in 2009, 2008 and 2007 by the Sunday Times Fast Track 100 fastest growing private technology companies review.
More details can be found at www.apatech.com
« BACK
